This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ørvim, U. Articles by Sakariassen, K. S. Search for Related Content PubMed PubMed Citation Articles by Ørvim, U. Articles by Sakariassen, K. S.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:2188-2194.)
© 1995 American Heart Association, Inc.

Articles

Effect of Selective Factor Xa Inhibition on Arterial Thrombus Formation Triggered by Tissue Factor/Factor VIIa or Collagen in an Ex Vivo Model of Shear-Dependent Human Thrombogenesis

Una Ørvim; R. Marius Barstad; George P. Vlasuk; Kjell S. Sakariassen

From Nycomed Pharma AS, Oslo, Norway, and Corvas International (G.P.V.), San Diego, Calif.

Correspondence to Una Ørvim, Nycomed Pharma AS, Gaustadalléen 21, 0371 Oslo, Norway. E-mail una.orvim@nycomed.telemax.no.

Abstract Tick anticoagulant peptide (TAP) is a potent and selective inhibitor of factor Xa. TAP has shown good antithrombotic efficacy in experimental animal models of disseminated intravascular coagulation and venous and arterial thrombogenesis. In the present study we evaluated the effect of recombinant TAP (rTAP) on acute thrombus formation in human nonanticoagulated blood triggered either by tissue factor (TF) or by collagen at arterial shear conditions. The main goal was to establish the role of factor Xa in thrombus formation by use of an optimal inhibitory concentration of rTAP. Blood was drawn directly from an antecubital vein by a pump over the respective thrombogenic surfaces, which were positioned in a parallel-plate perfusion chamber. rTAP was mixed homogeneously into the flowing blood by a heparin-coated device positioned proximal to the perfusion chamber. The passage of blood through this device caused minor activation of coagulation but little activation of platelets. Fibrinopeptide A and ß-thromboglobulin levels after 5 minutes of blood perfusion were, on average, 14 ng/mL and 45 IU/mL, respectively. rTAP at a plasma concentration of 0.90 µmol/L completely inhibited TF/factor VIIa–dependent thrombus formation at wall shear rates of 650 and 2600 s^-1. These shear conditions are comparable to those in medium-sized arteries and in moderately stenosed small arteries, respectively. In contrast to the TF-coated surface, rTAP was less efficient in reducing collagen-induced thrombus formation. While a significant reduction of 53% was observed at 650 s^-1, thrombus formation at 2600 s^-1 was not affected by rTAP. Thus, rTAP is an efficient inhibitor of thrombin-driven human thrombus formation on the TF-rich surface but less efficient when thrombus formation is elicited by type III collagen. The lack of antithrombotic effect on collagen type III at 2600 s^-1 corroborates earlier findings, showing that collagen-induced thrombus formation in blood from patients with severe factor VIII deficiency is not affected at this blood flow condition and thus is not dependent on the prothrombotic effects of thrombin.

Key Words: arterial thrombogenesis • tissue factor • collagen, factor Xa inhibition • rTAP

This article has been cited by other articles:

				D. Zhang, K. He, N. Raghavan, L. Wang, J. Mitroka, B. D. Maxwell, R. M. Knabb, C. Frost, A. Schuster, F. Hao, et al. Comparative Metabolism of 14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans Drug Metab. Dispos., August 1, 2009; 37(8): 1738 - 1748. [Abstract] [Full Text] [PDF]

				S. M. Bates and J. I. Weitz Emerging Anticoagulant Drugs Arterioscler Thromb Vasc Biol, September 1, 2003; 23(9): 1491 - 1500. [Abstract] [Full Text] [PDF]

				U. Rauch, J. I. Osende, V. Fuster, J. J. Badimon, Z. Fayad, and J. H. Chesebro Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences Ann Intern Med, February 6, 2001; 134(3): 224 - 238. [Abstract] [Full Text] [PDF]

				P. Zoldhelyi, J. McNatt, H. S. Shelat, Y. Yamamoto, Z.-Q. Chen, and J. T. Willerson Thromboresistance of Balloon-Injured Porcine Carotid Arteries After Local Gene Transfer of Human Tissue Factor Pathway Inhibitor Circulation, January 25, 2000; 101(3): 289 - 295. [Abstract] [Full Text] [PDF]

				J.-P. Bossavy, K. S. Sakariassen, C. Thalamas, B. Boneu, and Y. Cadroy Antithrombotic Efficacy of the Vitamin K Antagonist Fluindione in a Human Ex Vivo Model of Arterial Thrombosis : Effect of Anticoagulation Level and Combination Therapy With Aspirin Arterioscler Thromb Vasc Biol, September 1, 1999; 19(9): 2269 - 2275. [Abstract] [Full Text] [PDF]

				J. P. Bossavy, K. S. Sakariassen, K. Rubsamen, C. Thalamas, B. Boneu, and Y. Cadroy Comparison of the Antithrombotic Effect of PEG-Hirudin and Heparin in a Human Ex Vivo Model of Arterial Thrombosis Arterioscler Thromb Vasc Biol, May 1, 1999; 19(5): 1348 - 1353. [Abstract] [Full Text] [PDF]

				J.-P. Bossavy, C. Thalamas, L. Sagnard, A. Barret, K. Sakariassen, B. Boneu, and Y. Cadroy A Double-Blind Randomized Comparison of Combined Aspirin and Ticlopidine Therapy Versus Aspirin or Ticlopidine Alone on Experimental Arterial Thrombogenesis in Humans Blood, September 1, 1998; 92(5): 1518 - 1525. [Abstract] [Full Text] [PDF]

				U. Orvim, R. M. Barstad, L. Orning, L. B. Petersen, M. Ezban, U. Hedner, and K. S. Sakariassen Antithrombotic Efficacy of Inactivated Active Site Recombinant Factor VIIa Is Shear Dependent in Human Blood Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 3049 - 3056. [Abstract] [Full Text]